Med Tech Company Opposes Review Of Overturned $340M Antitrust Award

(March 3, 2017, 7:28 AM EST) -- WASHINGTON, D.C. — In a dispute over entitlement to a treble damages award for attempted monopolization under Section 2 of the Sherman Act, a medical technology company argues in a  Feb. 15 brief to the U.S. Supreme Court that there is no evidence that its alleged false advertising harmed competition or that it “tainted” the market by selling a flawed product (Retractable Technologies Inc. and Thomas Shaw v. Becton Dickinson & Co., No. 16-953, U.S. Sup.)....